PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Expenditure Sub-Program Areas track more specific PEPFAR expenditures.
Object classes provide highly specific ways that implementing partners are spending PEPFAR funds on programming.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
Beneficiary Expenditure data identify how PEPFAR programming is targeted at reaching different populations.
Sub-Beneficiary Expenditure data highlight more specific populations targeted for HIV prevention and treatment interventions.
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2008 2009
n/a
New/Continuing Activity: Continuing Activity
Continuing Activity: 17509
Continued Associated Activity Information
Activity Activity ID USG Agency Prime Partner Mechanism Mechanism ID Mechanism Planned Funds
System ID System ID
17509 17509.08 U.S. Agency for Family Health 7772 5606.08 TASC3 $200,000
International International
Development
Emphasis Areas
Human Capacity Development
Estimated amount of funding that is planned for Human Capacity Development $52,637
Public Health Evaluation
Food and Nutrition: Policy, Tools, and Service Delivery
Food and Nutrition: Commodities
Economic Strengthening
Education
Estimated amount of funding that is planned for Education $52,637
Water
Table 3.3.03:
Continuing Activity: 17512
17512 17512.08 U.S. Agency for Family Health 7772 5606.08 TASC3 $70,000
Estimated amount of funding that is planned for Human Capacity Development $21,000
Estimated amount of funding that is planned for Education $35,000
Table 3.3.06:
Continuing Activity: 17520
17520 17520.08 U.S. Agency for Family Health 7772 5606.08 TASC3 $10,000
Estimated amount of funding that is planned for Human Capacity Development $72,000
Estimated amount of funding that is planned for Food and Nutrition: Policy, Tools $6,000
and Service Delivery
Estimated amount of funding that is planned for Education $24,000
Table 3.3.08:
New/Continuing Activity: New Activity
Continuing Activity:
Estimated amount of funding that is planned for Human Capacity Development $27,500
Estimated amount of funding that is planned for Food and Nutrition: Policy, Tools $2,750
Estimated amount of funding that is planned for Education $11,000
Program Budget Code: 10 - PDCS Care: Pediatric Care and Support
Total Planned Funding for Program Budget Code: $120,000
Total Planned Funding for Program Budget Code: $0
Program Area Narrative:
Of the estimated 700,000 HIV infections in China at the end of 2007, approximately 7,000 (1%) occurred through MTCT. By the
end of June 2008, there were 4,200 cumulative pediatric HIV/ AIDS cases reported in China. Of these, 80% were from six
provinces (Anhui, Guangxi, Henan, Shanxi, Xinjiang, and Yunnan). The majority of pediatric HIV/AIDS cases are reported from
counties supported by China CARES or other government-led HIV/AIDS treatment and care programs.
Pediatric HIV/AIDS care policy is under the "Four Frees and One Care" policy issued by GoC in 2003. Due to limited capacity at
each level in implementing this policy, China initiated a pediatric HIV care program in several China CARES counties in Anhui and
Henan provinces in 2004, and then combined these with pediatric treatment programs (including OI prophylaxis) and expanded to
six GFATM Round 3-supported provinces in 2005 (resulting in the National Free HIV/AIDS Pediatric Treatment Program). By the
end of 2005, approximately 150 HIV- infected children were receiving ART. By August 2008, the program expanded to 22
provinces with approximately 1,200 infected children (ages 0-14 years) receiving ART. Of the children on ART, 91.8% are from
seven provinces: Henan (53.4%); Yunnan (10.6%); Guangxi (9.9%); Hubei (5.3%); Xinjiang (4.4%); Anhui (4.2%); and Shanxi
(4.2%).
Challenges faced by GoC in rolling out pediatric HIV/AIDS care and treatment include: 1) lack of capacity at the county level to
manage pediatric HIV care and support programs; 2) delay in early case finding; 3) poor adherence to medication in mostly rural
counties; 4) lack of linkages between PMTCT and pediatric programs; 5) late diagnosis and other factors leading to the median
age of HIV-infected children in HIV care to be 8 years; 6) lack of family and community support; and 7) stigma and discrimination
in communities and families.
Gaps in the National Free Pediatric AIDS Treatment program include: 1) poor integration of pediatric treatment with local pediatric
health services system; 2) limited cooperation between PMTCT and pediatric HIV treatment programs; 3) lack of capacity at the
county level to manage children infected with HIV; 4) lack of follow-up resulting in many HIV-infected children dying before they
can be put on ART; 5) poor ARV drug adherence for children and their family members, especially in rural areas; 6) lack of funds
for laboratory testing, regular clinical monitoring, and OI management; 7) poor quality of pediatric HIV treatment in Henan
province, where most of the cases are currently located; and 8) limited early case finding and referral for ART, which remains an
issue in high epidemic provinces such as Guangxi, Guizhou, Sichuan, Xinjiang, and Yunnan.
To help address these challenges and gaps, USG will work with Maternal and Child Health (MCH) and CDC systems on
strengthening cooperation between PMTCT and pediatric HIV/AIDS programs, and supporting development of a referral
mechanism between these two critical programs. USG will assist GoC in developing technical guidelines for early infant diagnosis
(EID) and transport of DBS specimens, and implementing the EID guidelines in at least the 333 PMTCT program counties. The
Clinton Foundation is providing regular monitoring, mentoring, and direct program support for pediatric HIV/AIDS care and
treatment in five provinces (Anhui, Guangxi, Henan, Xinjiang, and Yunnan). USG is working closely with the Clinton Foundation in
addressing gaps and barriers in pediatric HIV care and infant diagnosis by polymerase chain reaction (PCR).
USG will work with GFATM Round 3 and 4 offices (including the top six pediatric HIV/AIDS case load provinces) on strengthening
the three-tier health network system and involving families in providing quality care including OI management and medication
adherence support for HIV-exposed and -infected children. At the provincial level, USG will pilot home-based VCT and PITC
approaches in several high epidemic areas (e.g., Xinjiang and Yunnan) for early case detection and enrollment of more needy
children on care and treatment. USG will support all 15 USG-supported provinces in implementing the PwP strategy and
improving case management mechanisms for all HIV-infected children and their families to increase follow-up rates.
USG will continue to support graduates from the Lixin Rural AIDS Clinical Training Center on providing facility-based care and
support (including cotrimoxazole prophylaxis) to HIV-positive children in their respective provinces, including Anhui, Gangsu,
Guizhou, Heilongjiang, Henan, Hunan, Inner Mongolia, Jiangsu, Ningxia, Qinghai, Shandong, Sichuan, Tibet, Xinjiang, and
Yunnan. At least 24 physicians will be trained in pediatric HIV care and treatment each year. USG will also provide technical
assistance to NCAIDS on analysis and utilization of pediatric ART follow-up data.
The second-line ARV program started in Henan province in December 2007, and includes Abacavir (ABC), lamivudine (3TC), and
Kaletra. Tenofovir will become available before the end of 2008. GoC and the Clinton Foundation anticipate that approximately
200 children in five to six provinces will be on second-line therapy by December 2008. One national ARV drug resistance study in
2007 showed that the genotypic resistance to NRTI/NNRTI among HIV- infected children on first-line ARV therapy was quite high.
USG will assist in efforts to improve ARV drug adherence among HIV-infected children and their families.
Table 3.3.10:
Continuing Activity: 17517
17517 17517.08 U.S. Agency for Family Health 7772 5606.08 TASC3 $20,000
Estimated amount of funding that is planned for Human Capacity Development $2,600
Table 3.3.12:
Continuing Activity: 17515
17515 17515.08 U.S. Agency for Family Health 7772 5606.08 TASC3 $50,000
Estimated amount of funding that is planned for Human Capacity Development $30,000
Estimated amount of funding that is planned for Education $10,000
Program Budget Code: 15 - HTXD ARV Drugs
Not applicable
Program Budget Code: 16 - HLAB Laboratory Infrastructure
Total Planned Funding for Program Budget Code: $460,000
The USG China Five-Year Strategy for HIV/AIDS (2006-2010) aims to assist GoC in maintaining the HIV/AIDS prevalence below
1 per 1000 or 1.5 million HIV-infected persons nationwide by 2015 (in line with GoC, USG recently updated this to 2015). By the
end of 2007, China established an HIV testing network with 6,918 HIV antibody screening laboratories; and by August 2008, there
were 201 HIV antibody confirmatory laboratories in operation. There are 435 local CDC offices in generally low HIV prevalence
areas with no laboratories for HIV antibody screening.
The National AIDS Reference Laboratory (NARL) in NCAIDS is the HIV/AIDS Reference Laboratory in the China CDC system
and coordinates the network of HIV/AIDS laboratories nationwide. According to the most recent MoH strategy (2008), NARL is
also responsible for hepatitis C virus (HCV) testing, quality assurance/quality control (QA/QC), and syphilis QA/QC in the HIV
laboratory network. Since 2003, CDC China and USG have collaborated extensively on HIV BED incidence testing, HIV-2
diagnosis, and ARV drug resistance testing on DBS. Until recently, USG had limited involvement in other laboratory areas such as
evaluation of rapid test algorithms, rapid test reagent quality, and support for monitoring HIV treatment and care for patients.
In 2007, about 85,000 CD4 tests were conducted in China by laboratories nationwide. In the 24 provinces that have initiated viral
load testing, about 29,000 viral load tests were carried out in 2007. However, there are concerns about the test accuracy and
quality of training received by laboratory technicians in several of the provinces. Along with expanding the National Free ART
Program, by early 2008, 190 and 120 laboratories were equipped with instruments for CD4 and viral load testing, respectively. In
FY 2009, USG will focus on expanding and enhancing the QA/QC for HIV diagnosis and clinical monitoring, including HIV rapid,
CD4, and viral load testing at the provincial, prefecture, and county levels.
Along with the rapid expansion of these testing networks, personnel training and QA are critical for successful implementation at
all levels. At the national level, USG has assisted NARL in participating in a number of international QA networks. At the provincial
level, USG is supporting 15 provincial CDC laboratories to conduct QA twice a year. Since 2004, USG, through NARL, has
supported QA covering 2,987 laboratories, among which 2,927 (98%) were found to be qualified and 60 (2%) unqualified.
In FY 2009, USG will continue to support NCAIDS on the development of the most optimal HIV rapid testing algorithms, and help
implement standardized record keeping at HIV testing sites. In addition, QA elements and practical proficiency testing
approaches, such as the use of dried tube specimens, will be piloted. USG will provide technical assistance for post-marketing
surveillance of test kits to ensure the consistent quality of kits. USG will also work with NCAIDS to improve national CD4 testing
guidelines, and extend a proficiency testing system to the county level. USG will assist NCAIDS to revise and update the National
Guidelines for Detection of HIV/AIDS. In FY 2009, USG will assist NARL in developing national HCV testing guidelines. Along with
expansion of the National Free ART Program (by the end of August 2008, 52,191 persons had been enrolled on ART), USG will
support NARL to enhance the monitoring of drug resistance testing at the national level. At the provincial level, USG will support
Guangdong province and one other province (TBA) as a pilot to establish a network of drug resistance testing, appropriate
specimen transportation, and reporting.
USG has supported the implementation of BED-CEIA for HIV incidence estimation in seven provinces (Chongqing, Guangdong,
Guangxi, Guizhou, Sichuan, Xinjiang, and Yunnan) since 2005. In FY 2009, USG will support the development and
implementation of the national protocol for BED testing, including QA/QC, and extend this technology to one or two more
provinces. USG will focus on capacity building at the provincial and national levels in advanced statistical analysis and estimation
of HIV incidence trends among MARPs using BED data from multiple cross-sectional surveys. These estimations improve
projections of the spread of HIV regionally in China, and provide important feedback on the effectiveness of HIV prevention
programs such as those among IDU in different cities.
To strengthen early infant diagnosis of HIV, USG will support NARL and several provincial CDC laboratories in the use of DNA
PCR on infant DBS. Currently, very few HIV-infected infants in China are diagnosed in a timely manner to start ART in the first
year of life. The average age of children initiating ART in the past three years has been 8 years of age (see Pediatric Care,
Support, and Treatment narrative). As of September 2008, fewer than 10 out of more than 1,000 children on ART (<1%) are
infants. In FY 2009, USG will collaborate with the Clinton Foundation and NARL to develop a workable system for transportation
of specimens and timely return of PCR results to the field. Seventeen technicians in six provinces (Guangxi, Henan, Hubei,
Shandong, Shanghai, and Yunnan) have been trained on performing DNA PCR and the equipment has been installed; in addition,
NARL can provide regular QA/QC for all provincial EID laboratories.
To help achieve the above objectives, a senior laboratory scientist has been recruited and will join the USG China team in
January 2009 to work closely with the NARL, Clinton Foundation, and other partners. CDC Atlanta is assisting NARL to create a
medium- and long-term plan for strengthening HIV/AIDS laboratory capacity in China, and develop an HIV national laboratory
strategic plan for the next five years. In FY 2009, USG support will focus on: training a laboratory scientist on HIV drug resistance
genotyping using DBS; assisting with data analysis and timely delivery of HIV drug resistance data to practicing clinicians;
providing technical assistance on establishing a provincial HIV drug resistance testing network; assisting with BED-CEIA
incidence estimation and QA/QC; implementing new easy-to-use and cost-effective proficiency testing methods for HIV serologic
diagnostic QA; assisting with laboratory information systems; providing guidance to NARL in pursuing accreditation by
international laboratory accreditation agencies; and assisting with an evaluation of HIV rapid test and HCV test algorithms.
Table 3.3.16:
The PHE activity, "Enhanced Evaluation of ART Program in Guangxi Province, China" was approved for
inclusion in the FY09 Mini-COP. The PHE Tracking ID associated with this activity is: CN.07.0012.
Continuing Activity: 17523
17523 17523.08 U.S. Agency for Family Health 7772 5606.08 TASC3 $10,000
Estimated amount of funding that is planned for Public Health Evaluation $83,000
Table 3.3.17:
N/A
Estimated amount of funding that is planned for Human Capacity Development $20,000
Estimated amount of funding that is planned for Education $2,000
Program Budget Code: 18 - OHSS Health Systems Strengthening
Total Planned Funding for Program Budget Code: $1,316,326
Strengthening health systems within China is essential for sustaining the low prevalence of HIV/AIDS in the country. The Chinese
health infrastructure operates vertically, with each administrative level possessing firm command over the next lower level, from
the national to the provincial, prefecture, county, and township levels. Under this framework, USG-supported HIV/AIDS policy
activities work closely with GoC at all levels to effectively improve China's capacity to control this epidemic. In the USG China Five
-Year Strategy for HIV/AIDS (2006- 2010), a set of principles has been identified to accelerate and complement an effective
national response, which include supporting government policy development, building capacity for policy analysis, and fostering
an enabling environment at the community level.
At the national level, USG supports capacity building activities such as assisting NCAIDS divisions with annual work plans and
providing program management training. In addition, USG supports NCAIDS' efforts to pay close attention to capacity
development at the lower levels. Institutional capacity building of government partners is supported through the development of
management skills which are more participatory, inclusive, and respectful of the community's contribution.
In FY 2008, USG continued successful communication of the PwP strategy to GoC. Additionally, in a multi-year effort to change
the national MMT policy of NCAIDS, USG supported advocacy of recommendations to preferentially enroll PLHA in national MMT
programs. GoC's adaptation of the strategy is reflected in issuing national-level HIV/AIDS indicators that measure the number of
PLHA enrolled in MMT and the number of PLHA receiving palliative care and support. USG also supported NCAIDS in developing
national guidelines for the implementation of rapid testing, TB/HIV co-infection treatment, and ARV adherence. In FY 2009, USG
will initiate dialogue with NCAIDS to discuss how HIV/AIDS is financed in China and develop a plan for policy advocacy to
increase the amount of public financing. Through this effort, a better understanding of total resource mobilization towards
HIV/AIDS programming at the national, provincial, and county levels will result.
At the provincial and county levels, USG has focused efforts to address the lack of trained management and operational
personnel in underserved areas. USG's main strategy is to strengthen the public health system through two training programs to
improve human capacity: 1) the Lixin Anhui Rural AIDS Clinical Training Center, and 2) the Provincial Program Management
Training Program (PPMTP). Both programs are practical internships and provide comprehensive clinical home-based care,
support, and treatment under the mentorship of an HIV/AIDS US-trained clinician.
In its sixth year of operation, the Lixin Anhui Rural AIDS Clinical Training Center program is implemented through partnerships
with the Clinton Foundation, National Division for Care and Treatment, and the Anhui provincial health bureau. At the end of FY
2008, 71 clinicians from 31 provinces had been trained to better care for people with advanced HIV/AIDS. This is the only
practical clinical training program focused on the rural HIV/AIDS epidemic. In FY 2009, the training curriculum will be strengthened
by the involvement of the University of Washington's International Training and Education Center on HIV (I-TECH). The hope is to
double the number of participants by launching a second training center focused on advanced HIV disease among IDU. This
activity will be supported by a consortium of technical resources from the National Division of HIV/AIDS Care and Treatment,
Gates Foundation, and the local implementing unit.
PPMTP supports capacity building through a 6-month practical internship for 16 provincial HIV/AIDS personnel. Trainees identify
specific projects managed by technical experts in NCAIDS and are mentored under individual divisions. Because the Chinese
health system does not permit the transfer of provincial personnel to the national level, this training gives participants the
opportunity to learn from national programs, strengthen their contacts at the national level, improve their skills, and enhance
implementation at the provincial level. In FY 2009, PPMTP will expand the number of participants to include junior- and second-
level managers responsible for implementing HIV/AIDS activities.
USG will continue to assign technical advisors to GoC to better integrate USG efforts with the Chinese national and provincial
needs, ensure USG participation in HIV/AIDS annual provincial planning meetings, participate in strategic planning with the
NCAIDS, support NCAIDS' efforts to implement the "Three Ones" in every province, and assist in the acceptance of rapid testing
at the lower levels.
USG continues to provide technical assistance to GoC and other parties to prioritize and address pharmaceutical management
needs that have been identified to ensure an uninterrupted supply of quality ARV drugs and other pharmaceuticals and
commodities at ARV treatment sites. The ARV distribution system in China operates on five levels - provincial, prefectural,
county, township, and village health center. ARV procurement at the provincial, prefecture, county, and township levels operates
on a pull basis from the next highest level. The lead time needed to obtain drugs is five to 10 days. Village health centers obtain
their ARV supplies on a monthly basis. The system faces challenges as China rolls out ARV drugs on a wider basis; for example,
in Yunnan, 100 of 129 counties are currently providing ARV drugs and diagnostics. Establishment of a framework for appropriate
drug logistics management has become more important as the number of patients on ARV drugs in China rapidly increases.
In FY 2008, USG worked with local stakeholders in Guangxi province to strengthen ART management by providing technical
input, developing or adapting necessary tools and training materials, and providing follow-up support in implementing identified
interventions for ART. In addition, USG, through MSH, worked with WHO and MoH to explore potential technical assistance
needs related to the provision of ARV treatment in the GFATM Round 6 award. Based on an assessment conducted in Yunnan in
early 2007, serious recordkeeping and reporting issues were identified, such as inconsistent recording of inventory transactions;
lack of formal methods to control inventory at all levels; lack of records of consumption figures for ARV drugs; no formal methods
for estimating future needs; and weak monitoring of pharmaceutical management below the county level with no standardized
procedures.
Potential needs for technical assistance and support include: improving drug management information systems (stock
recordkeeping and regular reporting systems); strengthening the flow of information to and from village, township, and county
levels; enhancing methods for drug estimation and inventory control; developing monitoring and supervision systems for ARV
drugs and other medicines; and developing standard operating systems and providing on-the- job training to reinforce proper
procedures. In FY 2009, USG plans to expand the use of technical tools and training materials, while applying lessons learned
from Guangxi province, to strengthen ARV management in Yunnan. Specific proposed activities for Yunnan province include
conducting a stakeholders meeting, a workshop to assist national and provincial staff in introducing standard operating
procedures and tools for ARV management, and a training- of-trainers (TOT) workshop. USG will also provide follow-up support.
USG will focus on improving operational policies to support access to services, protection of rights, and harmonization of HIV legal
frameworks and policies that support community participation, including registration of NGOs. Importantly, USG will reposition
MARPs and PLHA to enable them to meaningfully participate in the policy process by strengthening their advocacy capacity,
supporting community mobilization, and consolidating community structures. All activities are underpinned by a commitment to
ensure the best quality data is driving decision making, and data is used for policy analysis, advocacy, and public consumption.
USG aims to demonstrate, document, and disseminate successful approaches to policy making and implementation that are
supportive of MARP and PLHA. USG works with the Chinese government to advocate that successful approaches to HIV policy
be replicated beyond Guangxi and Yunnan provinces.
In FY 2008, USG efforts at the community level focused on facilitating linkages between current community-level indigenous
organizations and provincial and county CDCs and health bureaus, particularly in Guangxi and Yunnan provinces where USG
supports many CBOs. USG has encouraged CBOs and GoC to engage in increased dialogue with provincial and local CDCs and
health bureaus to influence the policy process.
By providing small grants to regional PLHA networks to work with their national member organizations to transfer policy analysis
skills, USG has increased the ability of county networks to participate in national policy dialogue activities. To complement this
activity, USG assisted newly-formed networks to establish steering committees, and provided training to these groups in
advocacy, organization and financial management, and HIV/AIDS awareness. USG emphasizes the bottom-up approach to build
advocacy skills among local PLHA networks and MARP peer groups. Progress has been made on training and mobilizing them,
and ensuring buy-in and support from local governments to sustain indigenous organizations and link services they provide to
current government and other donor-provided services.
Strengthening local CBOs continues to be a focus of the USG China program. Adaptation of CBO capacity tools to the China
context is being carried out, and USG will use the CBO analysis toolkit to assess group development needs, analyze group
capacity, and assist groups in devising work plans focused on building capacity. Given the unique situation in China where it is not
possible for CBOs and NGOs to register unless they are affiliated with a government partner or agency, USG will simultaneously
build the capacity of government partners to enable them to effectively support these groups, which will require a similar
assessment and capacity building process as well as development of tailor-made tools for these partners. Given the relative
newness of CBOs among MARPs, many groups lack the expertise that could make them more sustainable and improve the
quality of life for their members. To address this situation, USG will begin building their expertise around savings-led, income-
generation options, micro-finance group mobilization and development, business planning, and simple marketing and accounting
skills.
In FY 2009, USG will support a variety of new and continuing efforts to support the strengthening of China's health system at the
national, provincial, county, and community levels. USG will continue its work on reducing stigma and discrimination against
MARPs and PLHA by measuring the extent to which national policies are known and understood. USG will employ MARPs and
PLHA to measure discrimination by health care providers after this year's implementation of the stigma and discrimination
curriculum in Guangxi. USG will measure discrimination among providers who have not been trained, and the range and
effectiveness of current incentives and sanctions for health care providers and public service personnel when discrimination does
occur. Results of this analysis will be incorporated into policy dialogue and advocacy activities.
USG will also work with local PSBs to improve their treatment of IDU and foster partnerships between local PSBs and CDCs to
increase referrals of IDU to MMT, thus complementing and building on the PwP work. USG will create opportunities for PSBs and
CDCs to engage in dialogue and harmonize public health and policing practices. Building on past regional meetings, USG will
convene groups of police and public health officials from the model communities to share emerging "best practices" on
interagency coordination and communication. Through joint efforts with GFATM Rounds 4 and 5, USG will support activities to
reduce stigma and discrimination specifically among MSM.
USG will support ongoing staff development activities and capacity building of local implementing partners in the areas of
advocacy, effective use and dissemination of data, and public relations. USG will support the brokering and provision of grants to
establish ‘twinning' relationships between young organizations and more established and accepted ones. USG will also monitor
developments in the formation of NGOs as the 10-year national poverty alleviation plan explicitly calls for increased NGO
involvement in anti-poverty activities.
USG will also continue to assist local policy makers, planners, and public officials in applying strategic information in planning and
advocacy for adequate HIV/AIDS resources with the A2 project. These types of activities are having tremendous impact, as noted
during a recent MoH presentation in Yunnan province where a decision to realign the HIV/AIDS budget was made after receiving
technical assistance from USG in this area.
Table 3.3.18:
Continuing Activity: 17524
17524 17524.08 U.S. Agency for Family Health 7772 5606.08 TASC3 $50,000
